Bridges Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$671K Sell
11,645
-1,104
-9% -$63.4K 0.01% 287
2026
Q1
$773K Sell
12,749
-1,312
-9% -$76.5K 0.01% 264
2025
Q4
$758K Buy
14,061
+276
+2% +$13.3K 0.01% 262
2025
Q3
$622K Sell
13,785
-221
-2% -$10.3K 0.01% 281
2025
Q2
$648K Buy
14,006
+80
+0.6% +$3.93K 0.01% 270
2025
Q1
$849K Hold
13,926
– – 0.01% 244
2024
Q4
$788K Sell
13,926
-243
-2% -$13.6K 0.01% 235
2024
Q3
$733K Sell
14,169
-431
-3% -$20.2K 0.01% 239
2024
Q2
$606K Buy
14,600
+1,971
+16% +$88.2K 0.01% 245
2024
Q1
$685K Sell
12,629
-100
-0.8% -$5.09K 0.02% 151
2023
Q4
$653K Hold
12,729
– – 0.02% 152
2023
Q3
$739K Hold
12,729
– – 0.03% 143
2023
Q2
$814K Sell
12,729
-685
-5% -$45.9K 0.03% 148
2023
Q1
$930K Hold
13,414
– – 0.03% 144
2022
Q4
$965K Sell
13,414
-2,050
-13% -$155K 0.04% 143
2022
Q3
$1.1M Sell
15,464
-1,000
-6% -$72.5K 0.04% 137
2022
Q2
$1.27M Hold
16,464
– – 0.05% 137
2022
Q1
$1.2M Sell
16,464
-1,400
-8% -$94K 0.04% 142
2021
Q4
$1.11M Sell
17,864
-5,690
-24% -$334K 0.03% 146
2021
Q3
$1.39M Sell
23,554
-198
-0.8% -$13K 0.04% 136
2021
Q2
$1.59M Sell
23,752
-250
-1% -$16.3K 0.05% 132
2021
Q1
$1.52M Sell
24,002
-963
-4% -$59.9K 0.04% 130
2020
Q4
$1.55M Sell
24,965
-3,067
-11% -$189K 0.05% 126
2020
Q3
$1.69M Sell
28,032
-688
-2% -$41.4K 0.06% 118
2020
Q2
$1.69M Sell
28,720
-2,445
-8% -$146K 0.06% 118
2020
Q1
$1.74M Sell
31,165
-13,781
-31% -$842K 0.08% 114
2019
Q4
$2.88M Sell
44,946
-11,898
-21% -$681K 0.11% 109
2019
Q3
$2.88M Buy
56,844
+13,411
+31% +$630K 0.11% 109
2019
Q2
$1.97M Buy
43,433
+10,457
+32% +$487K 0.08% 129
2019
Q1
$1.57M Sell
32,976
-416
-1% -$20.7K 0.06% 147
2018
Q4
$1.74M Buy
33,392
+2,351
+8% +$126K 0.08% 131
2018
Q3
$1.93M Sell
31,041
-10,483
-25% -$622K 0.1% 131
2018
Q2
$2.3M Buy
41,524
+2,315
+6% +$125K 0.1% 124
2018
Q1
$2.48M Buy
39,209
+19,095
+95% +$1.23M 0.11% 114
2017
Q4
$1.23M Buy
20,114
+350
+2% +$21.9K 0.1% 106
2017
Q3
$1.26M Buy
19,764
+6,693
+51% +$391K 0.12% 90
2017
Q2
$728K Buy
13,071
+517
+4% +$28.1K 0.1% 88
2017
Q1
$683K Hold
12,554
– – 0.09% 89
2016
Q4
$734K Buy
12,554
+388
+3% +$21.2K 0.1% 91
2016
Q3
$657K Hold
12,166
– – 0.11% 94
2016
Q2
$895K Hold
12,166
– – 0.15% 84
2016
Q1
$777K Buy
12,166
+427
+4% +$26.9K 0.14% 85
2015
Q4
$807K Sell
11,739
-414
-3% -$27.4K 0.14% 83
2015
Q3
$809K Hold
12,153
– – 0.14% 90
2015
Q2
$809K Buy
12,153
+400
+3% +$26.4K 0.14% 90
2015
Q1
$758K Sell
11,753
-700
-6% -$43.8K 0.13% 93
2014
Q4
$735K Buy
12,453
+2,400
+24% +$135K 0.13% 91
2014
Q3
$514K Buy
10,053
+400
+4% +$20K 0.1% 101
2014
Q2
$468K Buy
9,653
+553
+6% +$27.3K 0.09% 103
2014
Q1
$473K Buy
9,100
+967
+12% +$51.5K 0.1% 101
2013
Q4
$433K Hold
8,133
– – 0.1% 98
2013
Q3
$376K Sell
8,133
-1,000
-11% -$43.9K 0.09% 101
2013
Q2
$408K Buy
+9,133
New +$397K 0.11% 98

Other funds holding BMY

Bridges Investment Management's BMY Position: Q2 2026 in Review

Bridges Investment Management reduced its Bristol-Myers Squibb (BMY) stake by 8.7% in Q2 2026, selling an estimated $63.4K and leaving 11,645 shares worth $671K. The position accounts for 0.01% of the portfolio, ranked #287.

Bridges Investment Management first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.88M in Q4 2019. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Bridges Investment Management held 11,645 shares of Bristol-Myers Squibb worth $671K as of Q2 2026.
  • Bridges Investment Management sold 1,104 Bristol-Myers Squibb shares in Q2 2026, an estimated $63.4K.
  • Bristol-Myers Squibb made up 0.01% of Bridges Investment Management's portfolio in Q2 2026, its #287 holding.
  • Bridges Investment Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Bridges Investment Management's Bristol-Myers Squibb position peaked at $2.88M in Q4 2019.
  • 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Bridges Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.